Company intelligence / Profile preview

Cbio

Copenhagen, Denmarkpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Cbio has completed preclinical development of its lead product, novoleucel, a broad-spectrum T-cell therapy targeting late-stage solid tumors such as cervical cancer. The company is preparing to enter clinical trials in early 2025 and recently secured DKK 40 million (~$6M USD) financing to support this transition.[1][2] No human clinical results are available yet.

Therapeutic areas: Oncology
Modalities: T-cell therapies (cell therapy)
Industry: Biotech

Drug pipeline

1 asset

novoleucel

Preclinical

Partnerships

Clinical collaboration with Karolinska Institute, Stockholm for upcoming trials

Beyond the preview

Go deeper on Cbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cbio.

Explore the full profile